KIFLAM-SP

KIFLAM-SP, a flagship product from Solvista Healthcare, is a potent therapeutic combination designed to address a wide spectrum of painful and inflammatory conditions. Formulated as a tablet containing Aceclofenac, Paracetamol, and Serratiopeptidase, this “triple action” medication is engineered to provide rapid symptomatic relief while simultaneously addressing the underlying causes of tissue swelling and discomfort.

The Science of the Formula: Triple Action Synergy

The efficacy of KIFLAM-SP lies in its synergistic composition. Each ingredient targets a specific pathway in the body’s pain and inflammatory response:

1. Aceclofenac (NSAID): As a non-steroidal anti-inflammatory drug (NSAID), Aceclofenac works by inhibiting the cyclooxygenase (COX) enzymes. This action blocks the production of prostaglandins—the chemical messengers responsible for signaling pain and triggering inflammation at the site of injury or disease.

2. Paracetamol (Analgesic & Antipyretic): Paracetamol complements Aceclofenac by elevating the body’s overall pain threshold. It acts primarily on the central nervous system to reduce pain perception and serves as an effective antipyretic to manage associated fever.

3. Serratiopeptidase (Proteolytic Enzyme): This is the “secret weapon” of the SP combination. Serratiopeptidase is an enzyme that breaks down abnormal proteins (like fibrin) at the site of inflammation. By thinning the fluids around the injury, it enhances tissue repair, reduces edema (swelling), and allows the other two painkillers to reach the affected area more effectively.

Key Therapeutic Benefits

KIFLAM-SP is distinguished by its ability to offer more than just basic pain suppression. Its primary clinical advantages include:

• Powerful Anti-Inflammatory Action: By targeting multiple inflammatory mediators, it helps reduce the redness and heat associated with localized injuries.

• Faster Symptomatic Relief: The combination of a rapid-acting analgesic and a systemic enzyme ensures that patients feel better sooner compared to monotherapy.

• Reduction of Tissue Edema: It is particularly effective at “draining” the swelling that often complicates recovery from surgery or trauma.

• Enhanced Mobility: By reducing joint stiffness and pain, it helps patients return to their daily activities more quickly.

Clinical Indications

KIFLAM-SP is indicated for the management of mild to moderate pain and inflammation associated with:

• Orthopedic Conditions: Such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and lower back pain.

• Post-Operative Recovery: Helping to manage surgical site pain and swelling for smoother convalescence.

• Dental Procedures: Highly effective for post-extraction pain and inflammatory dental conditions.

• Musculoskeletal Disorders: Including sprains, strains, fibrositis, and sports injuries.

Quality Assurance and Manufacturing

Solvista Healthcare ensures that KIFLAM-SP is manufactured under stringent global standards. The product is backed by:

• WHO-GMP Certification: Ensuring that the tablets are consistently produced and controlled according to international quality standards.

• ISO Certification: Reflecting a commitment to standardized management systems and product safety.

• Quality Assured: Rigorous testing protocols to guarantee the purity and potency of the active pharmaceutical ingredients.